Even for those diagnosed at stage I, the five-year survival rate is still only between 12 and 14 percent.
That’s why Dr. Emma Fields, a radiation oncologist with VCU Massey Cancer Center, thought the CivaSheet — approved by the U.S. Food and Drug Administration in 2014 — might offer some hope to those patients. Read more . . .